Quantum X Labs Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or For the transition period from __________________ to __________________ Commission file number: 001-42681 QUANTUM X LABS INC. (Exact name of registrant as specified in its charter) VIEWBIX INC.(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer (as defined in Rule 12b-2 of theExchange Act) or a smaller reporting company. ☐Accelerated filer☒Smaller reporting companyEmerging growth company Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ PART I - FINANCIAL INFORMATION3ITEM 1.FINANCIAL STATEMENTS3ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS36ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK46ITEM 4.CONTROLS AND PROCEDURES46PART II - OTHER INFORMATION47ITEM 1.LEGAL PROCEEDINGS47ITEM 1A.RISK FACTORS47ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS47ITEM 3.DEFAULT UPON SENIOR SECURITIES47ITEM 4.MINE SAFETY DISCLOSURE48ITEM 5.OTHER INFORMATION48ITEM 6.EXHIBITS48SIGNATURES49-2- PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS QUANTUM X LABS INC. (formerly known as Viewbix Inc.) INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) March 31, 2026 CONTENTS QUANTUM X LABS INC. (formerly known as Viewbix Inc.)INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)U.S. dollars in thousands (except share data) The accompanying notes are an integral part of these Interim Condensed Consolidated financial statements. The accompanying notes are an integral part of these Interim Condensed Consolidated financial statements. QUANTUM X LABS INC. (formerly known as Viewbix Inc.)INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)U.S. dollars in thousands (except share data) QUANTUM X LABS INC. (formerly known as Viewbix Inc.)INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Cont.)U.S. dollars in thousands (except share data) QUANTUM X LABS INC. (formerly known as Viewbix Inc.)INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Cont.)U.S. dollars in thousands (except share data) Appendix A: As ofMarch 4, 2026Consolidation of Quantum Israel (see note 6.C):Net working capital other than cash and restricted deposits211Property and equipment9Goodwill14,326In-process research and development, net of deferred taxes1,232Non-controlling interests(79)Total consideration(15,892)Balance as of March 4, 2026(193)The accompanying notes are an integral part of these Interim Condensed Consolidated financial statements.-10- QUANTUM X LABS INC. (formerly known as Viewbix Inc.)NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)U.S. dollars in thousands (except share data) NOTE 1: GENERAL A. Organizational Background Quantum X Labs Inc. (formerly known as Viewbix Inc.) (the “Company”) was incorporated in the State of Delaware on August 16,1985, under a predecessor name, The InFerGene Company (“InFerGene Company”). On August 25, 1995, a wholly owned subsidiaryof InFerGene Company merged with Zaxis International, Inc., an Ohio corporation, which following such merger, the surviving entity,InFerGene Company, changed its name to Zaxis International, Inc. In 2015, the Company changed its name to Emerald MedicalApplications Corp., subsequent to which the Company, through its subsidiary, was engaged in the development of technology for usein detection of skin cancer. On January 29, 2018, the Company ceased its business operations in this field. On January 17, 2018, the Company formed a new wholly owned subsidiary under the laws of the State of Israel, Virtual CryptoTechnologies Ltd. (“VCT Isr